Retatrutide
Retatrutide Dosage calculations for
- Research frequency
- Once weekly by subcutaneous administration in the cited human trials.
- Weekly research range
- The cited programs evaluated target amounts through 12 mg weekly.
- Vial size
- The 10 mg label is total nominal vial content, not a weekly amount. Weekly research amounts above 10 mg require enough vials to supply the total nominal mass.
- Vial coverage
- At the 2 mg research stage, one vial supplies 5 full weekly amounts. At the 12 mg research stage, the 12 mg amount requires 2 separate 10 mg vials by nominal mass. These are mass calculations, not vial storage or discard periods.
Phase 2 Trial Schedule
| Study Phase | Weekly Dose | Volume |
|---|---|---|
| Weeks 1 to 4 | 2 mg | 0.2 mL |
| Weeks 5 to 8 | 4 mg | 0.4 mL |
| Weeks 9 to 12 | 8 mg | 0.8 mL |
| Weeks 13+ | 12 mg | 1.2 mL |
3 ml conversion
5 mg + 3 ml = 1.67 mg/ml. Choose your vial strength to update the units below.
| Source dose | U-100 syringe |
|---|---|
| 2 mg | 120 units |
| 4 mg | 240 units |
| 8 mg | 480 units |
| 12 mg | 720 units |